Robert Hazlett
Stock Analyst at BTIG
(1.31)
# 3,544
Out of 5,182 analysts
22
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $7.09 | +238.50% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $81.26 | -26.16% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.84 | +1,572.04% | 2 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $184.18 | -46.79% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.14 | +877.20% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $5.75 | +995.65% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $10.61 | +173.33% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $0.81 | +3,209,776.54% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.56 | +284.62% | 2 | Sep 4, 2020 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $18 | $20.29 | -11.29% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $7.09
Upside: +238.50%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $81.26
Upside: -26.16%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.84
Upside: +1,572.04%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $184.18
Upside: -46.79%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.14
Upside: +877.20%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $5.75
Upside: +995.65%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $10.61
Upside: +173.33%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $0.81
Upside: +3,209,776.54%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.56
Upside: +284.62%
KalVista Pharmaceuticals
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $20.29
Upside: -11.29%